Menu
The Galien Foundation
medal
Join us
    The Galien Foundation
      Prix Galien Medal
      Join us
      Prix Galien Coin
      Join us
      Join us
      What is happening
      Galien Image
      Prix Galien Korea

      Seoul Sep. 10

      Galien Image
      Prix Galien USA

      New York City Oct. 29

      Galien Image
      Prix Galien Bridges

      Stockholm Dec. 01

        Community
        Mission Partnership
        Recognition & Celebration
        Prix Galien International Galien Golden Jubliee Juries worldwide Prix Galien USA Roy Vagelos Pro Bono Humanum Award Prix Galien EcoHealth Prix Galien Bridges
        Prix Galien in the world Laureates Private sector since 1970 Pro Bono awards & Laureates Academic and Public sector since 1970 History of the Prize
        Education
        Galien Patient Summit Galien Week of Innovation Galien Forum USA Galien Forum Africa Galien Webinar Series Jerusalem Ethics Forum Top scientists & KOL Jury members worldwide
        Fueling the Debate
        Press releases Notable events Media Kit
        Submit your innovation
        Event Tickets
        Signup to our newsletter
        Contact
        Privacy Policy
        Terms of Service
        Speaker-1
        right_logo_2

        Celebrating 20 years of breakthroughs that transformed medicine; envisioning the next 20 years of frontiers to be crossed

        GALIEN PATIENT SUMMIT 2026

        No Decision for Me Without Me:

        Embedding Patient Expertise at the Heart of Innovation

        Thursday October 29th
        New York Academy of Medicine
        7:30 AM - 5:30 PM
        New York City

        The Galien Patient Summit creates a collaborative platform where patient voices, experiences, and needs directly shape the future of medical research, drug development, and healthcare delivery. 

        For the second year, the Galien Patient Summit will take place concurrently with the annual Galien USA Forum - the premiere industry meeting of the minds on the future of human health.

        Attend
        Co-Chairs

        Ken Frazier
        Michael Rosenblatt
        Philip Sharp
        Marc Tessier-Lavigne

        Speaker bios
        08:00
        OPENING CEREMONY
        Mask Group 381

        Prix Galien USA Awards

        in the categories
        • EcoHealth
        • Digital Health
        • Incubator / Accelerator / Equity
        • Startup
        Nominees Announcement in the category
        • MedTech
        PRESENTED BY:

        Ken Frazier, Prix Galien USA Committee Chair; Retired Chairman and Chief Executive Officer, Merck & Co., Inc.; Chairman, Health Assurance Initiatives, General Catalyst

        08:45 - 08:45

        The Patient-First Paradigm:
        How Patient Partnerships are Redefining and Bringing Value to Innovation  

        Chair
        Jeremy Abbate
        Patient First paradigm

        The next 20 years may demand not just smarter science, but the humility to admit how much we still don't know. Despite spectacular progress, we still can't cure metastatic cancer reliably, don't understand neurodegeneration's root causes, can't prevent autoimmune diseases, and struggle to explain the microbiome's role in health. Are we over-investing in targeted approaches while missing system-level insights? Will algorithms finally teach us what experiments couldn't, or must we wait for conceptual breakthroughs that no amount of data can substitute? Which current unknowns will become tomorrow's textbook basics and which will remain mysteries in 2046? Where do we need entirely new ways of thinking vs better tools?

        Chair

        Jeremy Abbate
        Vice President & Publisher, Scientific American

        David Fajgenbaum
        Co-Founder & President, Every Cure; Associate Professor of Medicine, University of Pennsylvania

        Kathy Giusti
        Founder, Multiple Myeloma Research Foundation; Author, Fatal to Fearless

        Cheryl Lubbert
        CEO & Co-Founder, Reverba Global

        Kate Sasser
        Chief Scientific Officer, Tempus AI

        Speaker Bios
        09:55 - 10:50

        The Future of Clinical Trials:
        Decentralized, Digital, and Designed with and for Patients 

        Chair
        Amy P. Abernethy
        Clinical_Trials

        The next 20 years may demand not just smarter science, but the humility to admit how much we still don't know. Despite spectacular progress, we still can't cure metastatic cancer reliably, don't understand neurodegeneration's root causes, can't prevent autoimmune diseases, and struggle to explain the microbiome's role in health. Are we over-investing in targeted approaches while missing system-level insights? Will algorithms finally teach us what experiments couldn't, or must we wait for conceptual breakthroughs that no amount of data can substitute? Which current unknowns will become tomorrow's textbook basics and which will remain mysteries in 2046? Where do we need entirely new ways of thinking vs better tools?

        Chair

        Amy P. Abernethy
        Co-Founder, Highlander Health; former Principal Deputy Commissioner, FDA 

        Michaela Dinboeck
        Head, Patient Engagement, Novartis

        Belen Fraile Ortiz
        Chief Data Science Officer, Innovative Research & Development, Johnson & Johnson

        Jan Geissler
        CEO & Founder, Patvocates

        Speaker Bios
        11:05 - 12:00

        Pricing, Access & Equity through an ALS Lens:
        Building Sustainable Innovation Patients Can Actually Access

        Chair
        Thomas Lines

        The next 20 years may demand not just smarter science, but the humility to admit how much we still don't know. Despite spectacular progress, we still can't cure metastatic cancer reliably, don't understand neurodegeneration's root causes, can't prevent autoimmune diseases, and struggle to explain the microbiome's role in health. Are we over-investing in targeted approaches while missing system-level insights? Will algorithms finally teach us what experiments couldn't, or must we wait for conceptual breakthroughs that no amount of data can substitute? Which current unknowns will become tomorrow's textbook basics and which will remain mysteries in 2046? Where do we need entirely new ways of thinking vs better tools?

        Chair

        Thomas Lines
        CEO & Chairman, Quercis Pharma

        Calaneet Balas
        President & CEO, The ALS Association

        Indu Navar
        CEO & Founder, Everything ALS

        Yentli Soto Albrecht
        Co-Founder, CureC9

        Sheri Strahl
        President & CEO, ALS Network  

        Speaker Bios
        Joint Sessions with the Galien Forum
        Luncheon Debate

        The Science Trust Conundrum:
        When Society Doubts its Own Progress

        Chair
        Jeremy Levin
        In partnership: forum_loog

        Billions of people walk through their days protected from measles, mumps, and polio without a moment's thought; the vaccines worked so well we forgot why we needed them. This is the paradox of scientific success: the better it works, the more invisible it becomes, and the easier it is to doubt. Meanwhile, foundational research funding is contracting. The pipeline of serendipitous discovery (the stochastic process that eventually yields breakthroughs no one predicted) is narrowing. The consequences won't be visible for 10-15 years. By then, it's too late to course-correct. How does an industry that speaks in clinical endpoints and p-values make its case to a society increasingly skeptical of expertise? What's the role of scientists, industry leaders, and institutions in rebuilding trust, and where have our own behaviors contributed to its erosion?

        Chair

        Jeremy Levin
        Executive Chairman, Ovid Therapeutics; Former Chair, BIO

        Gil Bashe
        Chair of Global Health & Purpose, Finn Partners

        Julie Fleshman
        President & CEO, Pancreatic Cancer Action Network

        Margaret Hamburg
        Co-President, InterAcademy Partnership; Former Commissioner, FDA

        Vardit Ravitsky
        President, Hastings Center for Bioethics;
        Senior Lecturer on Global Health and Social Medicine, Harvard Medical School

        Speaker Bios
        Keynote Address

        20 Years in 20 Minutes:
        A History & Lessons for the Next 2 Decades 

        Atul Gawande, Fish Chair in Surgery, Brigham and Women’s Hospital; Samuel O. Thier Professor of the Practice, Harvard Medical School; Distinguished Professor in Residence, Ariadne Labs

        The next 20 years may demand not just smarter science, but the humility to admit how much we still don't know. Despite spectacular progress, we still can't cure metastatic cancer reliably, don't understand neurodegeneration's root causes, can't prevent autoimmune diseases, and struggle to explain the microbiome's role in health. Are we over-investing in targeted approaches while missing system-level insights? Will algorithms finally teach us what experiments couldn't, or must we wait for conceptual breakthroughs that no amount of data can substitute? Which current unknowns will become tomorrow's textbook basics and which will remain mysteries in 2046? Where do we need entirely new ways of thinking vs better tools?

        13:30 - 14:25

        The Role of AI & Real-World Evidence in Regulatory Pathways and Speed to Market 

        Chair
        Becky Quick (TBC)
        AI_and_Real-world

        The next 20 years may demand not just smarter science, but the humility to admit how much we still don't know. Despite spectacular progress, we still can't cure metastatic cancer reliably, don't understand neurodegeneration's root causes, can't prevent autoimmune diseases, and struggle to explain the microbiome's role in health. Are we over-investing in targeted approaches while missing system-level insights? Will algorithms finally teach us what experiments couldn't, or must we wait for conceptual breakthroughs that no amount of data can substitute? Which current unknowns will become tomorrow's textbook basics and which will remain mysteries in 2046? Where do we need entirely new ways of thinking vs better tools?

        Chair

        Becky Quick
        Co-Anchor, CNBC Squawk Box (TBC) 

        Michael Boyle
        President & CEO, Cystic Fibrosis Foundation; Adjunct Professor of Medicine, Johns Hopkins School of Medicine

        Tara Frenkl
        SVP, Head of Global Medical Strategy & Integrated Evidence Generation, Bayer

        Daphne Koller
        CEO & Founder, insitro

        Janet Woodcock
        Former Principal Deputy Commissioner, USFDA and longtime Director, Center for Drug Evaluation and Research

        Speaker Bios
        14:35 - 14:55
        INAUGURAL PRIZE
        Mask Group 381

        Inaugural Prix Galien Patient First Award Ceremony in Honor of Michael J. Fox

        PRESENTED BY:
        17:15 pm
        Forum 2026 closing